Poolbeg raises £3.5M placing to fund cancer and obesity trials
What's the deal? Poolbeg PharmaDealroom has a profile for this one. Try Dealroom → has raised £3.5 million through a share placing to fund late-stage cancer and obesity trials. The clinical-stage biopharmaceutical company issued 58.3 million new shares at 6 pence each — a 16% discount to the prior close. Executive chair Cathal Friel contributed £250,000.
Why now? The raise, contingent on AIM admission expected July 21, 2026, extends Poolbeg's cash runway into the second quarter of 2028. It also supports ongoing partnering talks.
What's the endgame? Proceeds will complete the POLB 001 TOPICAL trial in multiple myeloma patients and an oral GLP-1 proof-of-concept obesity trial. Poolbeg is targeting two large markets: cancer immunotherapy and metabolic treatment.
POLB 001 is an orally delivered p38 MAP kinase inhibitor aimed at cytokine release syndrome, a common obstacle in cancer immunotherapy. The TOPICAL trial draws free supply of teclistamab from Johnson & JohnsonDealroom has a profile for this one. Try Dealroom → and sits within the broader RISE CRS research programme.
What could go wrong? Poolbeg remains pre-revenue, with sustained losses and cash burn. Its current market capitalisation stands at £49.36 million, and the placing was struck at a discount.
The signal: The quick re-raise reflects the funding demands facing clinical-stage biotechs, which must keep topping up cash to reach data catalysts. For Poolbeg, securing runway to 2028 buys time to turn early trial results into a partnering deal.
Image credit: Generated with Gemini
